Evidence map›Paper›PMID 41282841›Full record

ArticlemedRxiv : the preprint server for health sciences2025

HIV, Nephrotoxic Medications, and Chronic Kidney Disease: Prevalence, Risk Factors, and Mediation Analyses Among People With and Without HIV Enrolled in the Multicenter AIDS Cohort Study (MACS) / Women's Interagency HIV Study (WIHS) Combined Cohort Study.

Yue Pan, Dominique Musselman, Zain Mithani, Weiqun Tong, Joseph Margolick, Frank J Palella, Matthew J Mimiaga, Kaitlin Bodnar, Deborah Konkle-Parker, Gina Wingood and 11 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Yue PanDepartment of Public Health Sciences, University of Miami.
Dominique MusselmanDepartment of Psychiatry and Behavioral Sciences, University of Miami.
Zain MithaniDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine.
Weiqun TongDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health.
Joseph MargolickDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health.
Frank J PalellaDepartment of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine.
Matthew J MimiagaDepartment of Epidemiology, UCLA Fielding School of Public Health and Department of Psychiatry and Biobehavioral Sciences, UCLA Geffen School of Medicine, Los Angeles, CA, USA.
Kaitlin BodnarDepartment of Medicine, Division of Infectious Diseases, University of Pittsburgh.
Deborah Konkle-ParkerSchools of Nursing, Medicine and Population Health, University of Mississippi Medical Center.
Gina WingoodDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University.
Daniel WestreichDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.
Eric SeabergDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health.
Signe LaurenDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health.
Mardge CohenDepartment of Medicine, Rush University Medical Center; Cook County Health & Hospitals System.
Michelle M EstrellaDivision of Nephrology, Department of Medicine, University of California, San Francisco; San Francisco VA Health Care System.ORCID 0000-0002-8902-9576
Amanda SpenceDivision of Infectious Diseases, Department of Medicine, Georgetown University.
Tracey WilsonDepartment of Community Health Sciences, School of Public Health, SUNY Downstate Health Sciences University.
Michael RossDepartment of Medicine (Nephrology), Albert Einstein College of Medicine.
Dan FeasterDepartment of Public Health Sciences, University of Miami.
Maria L AlcaideDepartment of Medicine, OB/GYN, and Public Health Sciences. University of Miami Miller School of Medicine.
Deborah L JonesDepartment of Psychiatry and Behavioral Sciences, University of Miami.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
SF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3M
Sex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8M
Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7M
Sex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2M
NCATS NIH HHS KL2 TR001432NCATS NIH HHS TL1 TR001431NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR001409NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR003098NHLBI NIH HHS U01 HL146192NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146208NHLBI NIH HHS U01 HL146240NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NHLBI NIH HHS U01 HL146333NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI073961NIAID NIH HHS P30 AI124414NIMH NIH HHS P30 MH116867
6 · The paper itself

Abstract

Background: Chronic kidney disease (CKD) affects over 37 million adults in the United States, and people living with HIV (PLWH) are at greater risk for progression to end-stage kidney disease. Although both conditions are common among PLWH, the potential pathways through which depression and use of medications with nephrotoxic potential may influence CKD development remain underexplored. We evaluated the relationships of depression and nephrotoxic medication use with CKD prevalence among PLWH, and investigated the potential mediating effects of these factors on the pathway to CKD among PLWH. Methods: We analyzed longitudinal data from the Multicenter AIDS Cohort Study (MACS)/Women's Interagency HIV Study (WIHS) Combined Cohort Study (MWCCS), collected between October 2018 and September 2021, to assess the prevalence of kidney dysfunction (eGFR <60 mL/min/1.73 m Results: Among 2,530 participants [1,622 PLWH and 908 people living without HIV (PLWoH)], CKD prevalence was higher in PLWH (18.1%) compared to PLWoH (9.7%). GEE analysis revealed that HIV serostatus was significantly associated with an increased risk of CKD (RR = 1.37, 95% CI: 1.28-1.48, p < 0.0001). Other significant factors included age (RR = 1.03, 95% CI: 1.03-1.03, p < 0.0001), non-Hispanic Black (RR = 1.19, 95% CI: 1.11-1.27, p < 0.0001) compared to non-Hispanic White, diabetes (RR = 1.26, 95% CI: 1.17-1.35, p < 0.0001), and higher income (RR = 0.99, 95% CI: 0.98-1.00, p = 0.005). Mediation analysis indicated that nephrotoxic medication use, accounted for a small but significant proportion of the HIV- CKD association (indirect effect OR = 1.02, 95% CI: 1.00-1.03, p = 0.02). Conclusions: While it is well established that PLWH have a higher prevalence of CKD compared to PLWoH, our findings suggest that nephrotoxic medication use may modestly amplify this risk. Although most of the risk appears to be attributable to the direct effects of HIV, these medications represent a modifiable contributor. PLWH receiving such treatments may benefit from closer kidney function monitoring. Future research should investigate additional psychosocial and behavioral contributors to CKD among PLWH, including depression.

Identifiers

PMID41282841
PMCPMC12637789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.